Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PL9643 is a novel selectively binder to melanocortin receptors that acts as MC1/MC5 receptor agonist drug candidate, which is being evaluated for the treatment of patients with Dry Eye Disease.
Lead Product(s): PL9643
Therapeutic Area: Ophthalmology Product Name: PL9643
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Acquisition January 03, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment January 02, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment December 20, 2023
Details:
PL9643 ophthalmic solution (topical eye drops) which is act as the melanocortin receptor agonists investigated for the treatment of patients with dry eye disease.
Lead Product(s): PL9643
Therapeutic Area: Ophthalmology Product Name: PL9643
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Psychiatry/Psychology Product Name: Vyleesi
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
BMT-701 (bremelanotide) is a synthetic peptide analogue of melanocyte stimulating hormone alpha (MSHα), and its metabolism is by hydrolysis of amide bonds and digestion by cellular peptidases.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Nephrology Product Name: BMT-701
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
PL8177 is a synthetic cyclic heptapeptide with efficacy in multiple animal inflammatory bowel disease models. PL8177 is a potent, selective agonist at the human melanocortin receptor-1, with sub-nanomolar affinity binding and EC50 functional values.
Lead Product(s): PL8177
Therapeutic Area: Gastroenterology Product Name: PL8177
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
PL8177 is a potent, selective agonist oral formulations at the human melanocortin receptor-1 (MC1r), with sub-nanomolar affinity binding and EC50 functional values.
Lead Product(s): PL8177
Therapeutic Area: Gastroenterology Product Name: PL8177
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022